Literature DB >> 21427068

Urinary albumin excretion within the normal range is an independent risk for near-term development of kidney disease in HIV-infected patients.

Minoru Ando1, Naoki Yanagisawa, Atsushi Ajisawa, Ken Tsuchiya, Kosaku Nitta.   

Abstract

BACKGROUND: Epidemiological studies have raised awareness of the problem of undiagnosed kidney disease and suggest that early identification and treatment will reduce the global burden of patients requiring dialysis. However, there are insufficient data on how to identify subjects who are at risk for developing overt kidney disease in a human immunodeficiency virus (HIV) population.
METHODS: A 2-year prospective cohort study was conducted to determine the predictors of overt kidney disease. The cohort was comprised of a total of 507 HIV-infected participants with no evidence of kidney disease at baseline. Of which 429 participants completed the study. New-onset kidney disease was defined as the development of either microalbuminuria or renal dysfunction. Microalbuminuria was defined as urinary albumin-to-creatinine ratio (ACR) ≥ 30 mg/g. Renal dysfunction was defined as an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m(2). Baseline ACR and eGFR were classified into three and two groups for analysis: 0-9, 10-19 and 20-29 mg/g and 60-89 and ≥ 90 mL/min/1.73 m(2), respectively. Cox proportional hazards regression analysis was used to determine the baseline factors related to incident kidney disease.
RESULTS: The incidence of microalbuminuria, renal dysfunction and both illness were 8.4, 4.7 and 0.93% during the 2-year follow-up period, respectively. Baseline predictors of the development of microalbuminuria included the following (hazard ratio with 95% confidence interval): (i) age, 1.03 (1.00-1.07); (ii) diabetes mellitus (DM), 4.41 (1.04-16.1); (iii) hepatitis C virus (HCV) coinfection, 7.91 (1.56-33.2); (iv) ACR 10-19 mg/g, 11.5 (3.51-52.6) and (v) ACR 20-29 mg/g, 49.0 (13.9-236). Baseline predictors of the development of renal dysfunction included the following: (i) age, 1.03 (1.00-1.12); (ii) baseline eGFR 60-89 mL/min/1.73 m(2), 7.86 (2.11-51.5); (iii) ACR 10-19 mg/g, 3.88 (1.28-12.6); (iv) ACR 20-29 mg/g, 6.64 (1.65-26.3) and (v) exposure to tenofovir-boosted protease inhibitors, 7.17 (2.57-23.4). The risks increased greatly with increasing number of concurrent predictors.
CONCLUSIONS: Middle to high levels within the normal range of albuminuria is a significant risk factor for near-term development of overt kidney disease. In particular, HIV-infected patients with multiple risk factors including age, DM, HCV, low-grade albuminuria, a mild decrease in eGFR and use of tenofovir-boosted protease inhibitors should be closely monitored.

Entities:  

Mesh:

Year:  2011        PMID: 21427068     DOI: 10.1093/ndt/gfr129

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  14 in total

1.  KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2018-09-19

2.  Increased non-HDL-C level linked with a rapid rate of renal function decline in HIV-infected patients.

Authors:  Masaki Hara; Naoki Yanagisawa; Akihito Ohta; Kumiko Momoki; Ken Tsuchiya; Kosaku Nitta; Minoru Ando
Journal:  Clin Exp Nephrol       Date:  2016-05-18       Impact factor: 2.801

Review 3.  Renal dysfunction in the setting of HIV/AIDS.

Authors:  Jose M Miro; Federico Cofan; Joan C Trullas; Christian Manzardo; Carlos Cervera; Montserrat Tuset; Federico Oppenheimer; Mercedes Brunet; Asuncion Moreno; Josep M Campistol; Jose M Gatell
Journal:  Curr HIV/AIDS Rep       Date:  2012-09       Impact factor: 5.071

Review 4.  How to manage HIV-infected patients with chronic kidney disease in the HAART era.

Authors:  Minoru Ando; Ken Tsuchiya; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2012-06       Impact factor: 2.801

Review 5.  Epidemiology, clinical characteristics, and management of chronic kidney disease in human immunodeficiency virus-infected patients.

Authors:  Minoru Ando; Naoki Yanagisawa
Journal:  World J Nephrol       Date:  2015-07-06

Review 6.  The burden of diabetes and hyperlipidemia in treated HIV infection and approaches for cardiometabolic care.

Authors:  Katherine Samaras
Journal:  Curr HIV/AIDS Rep       Date:  2012-09       Impact factor: 5.071

7.  Microalbuminuria in HIV disease.

Authors:  Colleen Hadigan; Elizabeth Edwards; Alice Rosenberg; Julia B Purdy; Estee Fleischman; Lilian Howard; JoAnn M Mican; Karmini Sampath; Akinbowale Oyalowo; Antoinette Johnson; Alexandra Adler; Catherine Rehm; Margo Smith; Leon Lai; Jeffrey B Kopp
Journal:  Am J Nephrol       Date:  2013-04-20       Impact factor: 3.754

8.  The role of albuminuria in the follow-up of HIV-infected pediatric patients.

Authors:  Angela Deyà-Martínez; Antoni Noguera-Julian; Jordi Vila; Anna Vila; Anna Valls; Emília Sánchez; Rafael Jiménez; Clàudia Fortuny
Journal:  Pediatr Nephrol       Date:  2014-04-16       Impact factor: 3.714

9.  Atazanavir nephrotoxicity.

Authors:  Masaki Hara; Akihiko Suganuma; Naoki Yanagisawa; Akifumi Imamura; Tsunekazu Hishima; Minoru Ando
Journal:  Clin Kidney J       Date:  2015-03-20

10.  Albuminuria Is Associated with Traditional Cardiovascular Risk Factors and Viral Load in HIV-Infected Patients in Rural South Africa.

Authors:  G Emerens Wensink; Annelot F Schoffelen; Hugo A Tempelman; Maarten B Rookmaaker; Andy I M Hoepelman; Roos E Barth
Journal:  PLoS One       Date:  2015-08-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.